Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04196491
Title A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4) (KarMMa-4)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Celgene

multiple myeloma



Cyclophosphamide + Fludarabine + Idecabtagene Vicleucel

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.